CD4 cell counts at the third month of HAART may predict clinical failure

Antonella D'Arminio Monforte, Valeria Testori, Fulvio Adorni, Barbara Castelnuovo, Teresa Bini, Letizia Testa, GianCarla Moscatelli, Elisabetta Chiesa, Stefano Rusconi, Clara Abeli, Salvatore Sollima, Massimo Musicco, Luca Meroni, Massimo Galli, Mauro Moroni

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Objective: To evaluate the influence of immunological and virological markers on clinical outcome in patients receiving their first highly active antiretroviral therapy (HAART) regimen. Design and methods: Observational study of 585 patients initiating HAART in a clinical setting. Clinical failure was defined as the occurrence of new or recurrent AIDS-defining events or death, and was analysed by means of intention-to-treat, univariate and multivariate analyses. An adjusted Cox regression model was used to evaluate the effect of 3-month CD4 cell counts on clinical outcome. Results: Clinical failure occurred in 55 patients (9.4%) during a median follow-up of 483 days (range 33-1334 days): 45 new AIDS-defining events (ADEs) in 38, ADE recurrence in six, and death in 11. Twenty-four of the 45 new ADEs (53.4%) occurred during the first 3 months of HAART, and 11 of 45 (24.4%) in the presence of CD4 cell counts > 200 x 106 cells/l. The mean (median, range) CD4 counts were 144 x 106 cells/l (128, 4-529) in patients with and 322 x 106 cells/l (288, 14-1162) in patients without clinical failure (P <0.0001). Moreover, the proportion of patients with mean CD4 cell counts <200 x 106 cells/l was higher in those experiencing subsequent clinical failure (χ2 test: 26.75; P <0.00001). Multivariate analysis showed that baseline CD4 cell counts <50 x 106 cells/l and AIDS at enrolment predicted failure; after adjusting for 3-month CD4 cell counts, this marker was the only one independently associated with clinical failure (hazard risk, 4.79; 95% confidence interval, 1.40-16.47). Conclusions: The 3-month immunological response is a reliable predictor of long-term clinical outcome.

Original languageEnglish
Pages (from-to)1669-1676
Number of pages8
JournalAIDS (London, England)
Volume13
Issue number13
DOIs
Publication statusPublished - 1999

Fingerprint

Highly Active Antiretroviral Therapy
CD4 Lymphocyte Count
Acquired Immunodeficiency Syndrome
Multivariate Analysis
Intention to Treat Analysis
Proportional Hazards Models
Observational Studies
Biomarkers
Confidence Intervals
Recurrence

Keywords

  • 3-month CD4 cell count
  • Clinical failure
  • Highly active antiretroviral therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

D'Arminio Monforte, A., Testori, V., Adorni, F., Castelnuovo, B., Bini, T., Testa, L., ... Moroni, M. (1999). CD4 cell counts at the third month of HAART may predict clinical failure. AIDS (London, England), 13(13), 1669-1676. https://doi.org/10.1097/00002030-199909100-00010

CD4 cell counts at the third month of HAART may predict clinical failure. / D'Arminio Monforte, Antonella; Testori, Valeria; Adorni, Fulvio; Castelnuovo, Barbara; Bini, Teresa; Testa, Letizia; Moscatelli, GianCarla; Chiesa, Elisabetta; Rusconi, Stefano; Abeli, Clara; Sollima, Salvatore; Musicco, Massimo; Meroni, Luca; Galli, Massimo; Moroni, Mauro.

In: AIDS (London, England), Vol. 13, No. 13, 1999, p. 1669-1676.

Research output: Contribution to journalArticle

D'Arminio Monforte, A, Testori, V, Adorni, F, Castelnuovo, B, Bini, T, Testa, L, Moscatelli, G, Chiesa, E, Rusconi, S, Abeli, C, Sollima, S, Musicco, M, Meroni, L, Galli, M & Moroni, M 1999, 'CD4 cell counts at the third month of HAART may predict clinical failure', AIDS (London, England), vol. 13, no. 13, pp. 1669-1676. https://doi.org/10.1097/00002030-199909100-00010
D'Arminio Monforte A, Testori V, Adorni F, Castelnuovo B, Bini T, Testa L et al. CD4 cell counts at the third month of HAART may predict clinical failure. AIDS (London, England). 1999;13(13):1669-1676. https://doi.org/10.1097/00002030-199909100-00010
D'Arminio Monforte, Antonella ; Testori, Valeria ; Adorni, Fulvio ; Castelnuovo, Barbara ; Bini, Teresa ; Testa, Letizia ; Moscatelli, GianCarla ; Chiesa, Elisabetta ; Rusconi, Stefano ; Abeli, Clara ; Sollima, Salvatore ; Musicco, Massimo ; Meroni, Luca ; Galli, Massimo ; Moroni, Mauro. / CD4 cell counts at the third month of HAART may predict clinical failure. In: AIDS (London, England). 1999 ; Vol. 13, No. 13. pp. 1669-1676.
@article{e56b07849efe4532b63421cadf98e041,
title = "CD4 cell counts at the third month of HAART may predict clinical failure",
abstract = "Objective: To evaluate the influence of immunological and virological markers on clinical outcome in patients receiving their first highly active antiretroviral therapy (HAART) regimen. Design and methods: Observational study of 585 patients initiating HAART in a clinical setting. Clinical failure was defined as the occurrence of new or recurrent AIDS-defining events or death, and was analysed by means of intention-to-treat, univariate and multivariate analyses. An adjusted Cox regression model was used to evaluate the effect of 3-month CD4 cell counts on clinical outcome. Results: Clinical failure occurred in 55 patients (9.4{\%}) during a median follow-up of 483 days (range 33-1334 days): 45 new AIDS-defining events (ADEs) in 38, ADE recurrence in six, and death in 11. Twenty-four of the 45 new ADEs (53.4{\%}) occurred during the first 3 months of HAART, and 11 of 45 (24.4{\%}) in the presence of CD4 cell counts > 200 x 106 cells/l. The mean (median, range) CD4 counts were 144 x 106 cells/l (128, 4-529) in patients with and 322 x 106 cells/l (288, 14-1162) in patients without clinical failure (P <0.0001). Moreover, the proportion of patients with mean CD4 cell counts <200 x 106 cells/l was higher in those experiencing subsequent clinical failure (χ2 test: 26.75; P <0.00001). Multivariate analysis showed that baseline CD4 cell counts <50 x 106 cells/l and AIDS at enrolment predicted failure; after adjusting for 3-month CD4 cell counts, this marker was the only one independently associated with clinical failure (hazard risk, 4.79; 95{\%} confidence interval, 1.40-16.47). Conclusions: The 3-month immunological response is a reliable predictor of long-term clinical outcome.",
keywords = "3-month CD4 cell count, Clinical failure, Highly active antiretroviral therapy",
author = "{D'Arminio Monforte}, Antonella and Valeria Testori and Fulvio Adorni and Barbara Castelnuovo and Teresa Bini and Letizia Testa and GianCarla Moscatelli and Elisabetta Chiesa and Stefano Rusconi and Clara Abeli and Salvatore Sollima and Massimo Musicco and Luca Meroni and Massimo Galli and Mauro Moroni",
year = "1999",
doi = "10.1097/00002030-199909100-00010",
language = "English",
volume = "13",
pages = "1669--1676",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",
number = "13",

}

TY - JOUR

T1 - CD4 cell counts at the third month of HAART may predict clinical failure

AU - D'Arminio Monforte, Antonella

AU - Testori, Valeria

AU - Adorni, Fulvio

AU - Castelnuovo, Barbara

AU - Bini, Teresa

AU - Testa, Letizia

AU - Moscatelli, GianCarla

AU - Chiesa, Elisabetta

AU - Rusconi, Stefano

AU - Abeli, Clara

AU - Sollima, Salvatore

AU - Musicco, Massimo

AU - Meroni, Luca

AU - Galli, Massimo

AU - Moroni, Mauro

PY - 1999

Y1 - 1999

N2 - Objective: To evaluate the influence of immunological and virological markers on clinical outcome in patients receiving their first highly active antiretroviral therapy (HAART) regimen. Design and methods: Observational study of 585 patients initiating HAART in a clinical setting. Clinical failure was defined as the occurrence of new or recurrent AIDS-defining events or death, and was analysed by means of intention-to-treat, univariate and multivariate analyses. An adjusted Cox regression model was used to evaluate the effect of 3-month CD4 cell counts on clinical outcome. Results: Clinical failure occurred in 55 patients (9.4%) during a median follow-up of 483 days (range 33-1334 days): 45 new AIDS-defining events (ADEs) in 38, ADE recurrence in six, and death in 11. Twenty-four of the 45 new ADEs (53.4%) occurred during the first 3 months of HAART, and 11 of 45 (24.4%) in the presence of CD4 cell counts > 200 x 106 cells/l. The mean (median, range) CD4 counts were 144 x 106 cells/l (128, 4-529) in patients with and 322 x 106 cells/l (288, 14-1162) in patients without clinical failure (P <0.0001). Moreover, the proportion of patients with mean CD4 cell counts <200 x 106 cells/l was higher in those experiencing subsequent clinical failure (χ2 test: 26.75; P <0.00001). Multivariate analysis showed that baseline CD4 cell counts <50 x 106 cells/l and AIDS at enrolment predicted failure; after adjusting for 3-month CD4 cell counts, this marker was the only one independently associated with clinical failure (hazard risk, 4.79; 95% confidence interval, 1.40-16.47). Conclusions: The 3-month immunological response is a reliable predictor of long-term clinical outcome.

AB - Objective: To evaluate the influence of immunological and virological markers on clinical outcome in patients receiving their first highly active antiretroviral therapy (HAART) regimen. Design and methods: Observational study of 585 patients initiating HAART in a clinical setting. Clinical failure was defined as the occurrence of new or recurrent AIDS-defining events or death, and was analysed by means of intention-to-treat, univariate and multivariate analyses. An adjusted Cox regression model was used to evaluate the effect of 3-month CD4 cell counts on clinical outcome. Results: Clinical failure occurred in 55 patients (9.4%) during a median follow-up of 483 days (range 33-1334 days): 45 new AIDS-defining events (ADEs) in 38, ADE recurrence in six, and death in 11. Twenty-four of the 45 new ADEs (53.4%) occurred during the first 3 months of HAART, and 11 of 45 (24.4%) in the presence of CD4 cell counts > 200 x 106 cells/l. The mean (median, range) CD4 counts were 144 x 106 cells/l (128, 4-529) in patients with and 322 x 106 cells/l (288, 14-1162) in patients without clinical failure (P <0.0001). Moreover, the proportion of patients with mean CD4 cell counts <200 x 106 cells/l was higher in those experiencing subsequent clinical failure (χ2 test: 26.75; P <0.00001). Multivariate analysis showed that baseline CD4 cell counts <50 x 106 cells/l and AIDS at enrolment predicted failure; after adjusting for 3-month CD4 cell counts, this marker was the only one independently associated with clinical failure (hazard risk, 4.79; 95% confidence interval, 1.40-16.47). Conclusions: The 3-month immunological response is a reliable predictor of long-term clinical outcome.

KW - 3-month CD4 cell count

KW - Clinical failure

KW - Highly active antiretroviral therapy

UR - http://www.scopus.com/inward/record.url?scp=16744365520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16744365520&partnerID=8YFLogxK

U2 - 10.1097/00002030-199909100-00010

DO - 10.1097/00002030-199909100-00010

M3 - Article

C2 - 10509568

AN - SCOPUS:16744365520

VL - 13

SP - 1669

EP - 1676

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 13

ER -